EGFR and non-small cell lung carcinoma: In this study, the PET/CT Rad-score successfully achieved accurate quantification of the risk of progression after first-line first and second generation EGFR-TKI drug therapy in stage IIIC/IV EGFR-mutated NSCLC patients and identified first and second generation EGFR-TKI treatment-sensitive populations.